IMRX
NASDAQ HealthcareImmuneering Corporation - Class A Common Stock
Biotechnology
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $5.56 |
|---|---|
| 成交量 | 795,614 |
| 市值 | 359.47M |
| 贝塔系数 | 0.430 |
| RSI（14日） | 62.3 |
| 200日均线 | $5.59 |
| 50日均线 | $5.19 |
| 52周最高 | $10.08 |
| 52周最低 | $1.10 |
| Forward P/E | -4.11 |
| Price / Book | 1.64 |
🎯 投资策略评分
IMRX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (70/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 IMRX in your text
粘贴任何文章、记录或帖子 — 工具将提取 IMRX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.